Phost’in Therapeutics and the Gianni Bonadonna Foundation To Present First Clinical Data on PhOx430, a First-In-Class GnT-V Inhibitor, at ESMO 2025

Montpellier, France and Milan, Italy – October 2, 2025

Phost’in Therapeutics SAS (Montpellier, France),

Phost’in Therapeutics, a clinical-stage biotechnology company focused on the development of N-glycosylation inhibitors and the Fondazione Gianni Bonadonna, which provides scientific contribution and independent support, will jointly present a poster on interim clinical data from the PhAST trial at the European Society for Medical Oncology (ESMO) Annual Congress 2025, held October 17–21 in Berlin, Germany.